All In Biotech

Free tool

FAERS Monitor: Klaron

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019931 or its brand name (Klaron, Sulfacetamide Sodium). Reports on generic versions are filed under their own applications.

Reports

580

Serious

250

43% of reports

Hospitalization

91

Death reported

15

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug hypersensitivity66
  • drug ineffective55
  • nausea36
  • off label use35
  • headache31
  • pain30
  • dyspnoea29
  • rash28
  • fatigue25
  • weight decreased24
  • vomiting20
  • diarrhoea19
  • erythema19
  • pruritus19
  • asthenia18

Reports by year received

View as table
YearReports
20042
200510
20063
20078
20085
200912
201020
201114
201218
201325
201413
201525
201649
201738
201842
201954
202031
202125
202249
202335
202432
202535
202635

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,579 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug hypersensitivitySignal6612.49.9685
erythemaSignal193.42.229
weight decreasedSignal243.12.133
rashSignal282.31.620
dyspnoea291.91.311
headache311.81.310
pruritus191.81.26
pain301.81.210
asthenia181.71.15
nausea361.61.29
vomiting201.51.03
drug ineffective551.51.210
off label use351.41.15
fatigue251.20.80
diarrhoea191.10.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.